Long-term outcome of intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia

Session Details

Session Title: Free Paper Session 16: Vascular Diseases & Diabetic Retinopathy IV

Session Date/Time: Friday 08/09/2017 | 16:30-18:00

Paper Time: 16:54

Venue: Room 114

First Author: : A.Korol UKRAINE

Co Author(s): :    T. Kustryn   O. Blavatska                          

Abstract Details

Purpose:

To evaluate the long-term efficacy of intravitreal aflibercept injections for the treatment patients with choroidal neovascularization associated with pathologic myopia.

Setting:

SI “The Filatov`s Institute of Eye Diseases and Tissue Therapy of NAMS of Ukraine”

Methods:

In an uncontrolled, prospective time series cohort study, 39 eyes of 37 consecutive patients affected by a choroidal neovascularization associated with pathologic myopia and treated with intravitreal aflibercept (2.0 mg) pro re nata (PRN) following 2 initial monthly doses and observed over a 24 months follow-up period. The primary endpoint was change in best-corrected visual acuity (BCVA) at month 24, while central retinal thickness (CRT) on optical coherence tomography (OCT), number of aflibercept injections administered and safety, were examined as secondary endpoints.

Results:

The mean decimal BCVA was significantly improved from 0.21 (0.15) at baseline to 0.38 (0.21) (p=0.0001) at month 24. The mean CRT on OCT significant decreased from 274 (44) mcm at baseline to 224 (39) mcm (p=0.0001) at month 24. The mean number of intravitreal aflibercept injections was 2.6 (0.9) at the end of 12 months and 2.8 (1.1) at the end of the 24 months. No cases of endophthalmitis, uveitis, stroke, or retinal detachment were noted. No patient demonstrated an intraocular pressure >20 mm Hg in any study visit.

Conclusions:

The 24-month results of intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia using a PRN regimen were positive, with benefits on visual and anatomical outcomes, and an acceptable tolerability profile.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy